Evidence map›Paper›PMID 31647025›Full record

Trial reportArthritis research & therapy2019

Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.

Victor Farutin, Thomas Prod'homme, Kevin McConnell, Nathaniel Washburn, Patrick Halvey, Carol J Etzel, Jamey Guess, Jay Duffner, Kristen Getchell, Robin Meccariello and 14 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Arthritis research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 1 country.

Victor FarutinMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Thomas Prod'hommeMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Kevin McConnellMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Nathaniel WashburnMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Patrick HalveyMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Carol J EtzelCorrona LLC, Waltham, MA, USA.
Jamey GuessMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Jay DuffnerMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Kristen GetchellMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Robin MeccarielloMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Bryan GutierrezMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Christopher HonanMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Ganlin ZhaoMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Nicholas A CilfoneMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Nur Sibel GunayMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Jan L HillsonMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
David S DeLucaDeLuca Data Science, Wietze, Germany.
Katherine C SaundersCorrona LLC, Waltham, MA, USA.
Dimitrios A PappasCorrona LLC, Waltham, MA, USA.
Jeffrey D GreenbergCorrona LLC, Waltham, MA, USA.
Joel M KremerCorrona LLC, Waltham, MA, USA.
Anthony M ManningMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Leona E LingMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA. lling@momentapharma.com.
Ishan CapilaMomenta Pharmaceuticals Inc., 301 Binney Street, Cambridge, MA, 02142, USA. icapila@gmail.com.ORCID 0000-0002-5036-6778
Momenta Pharmaceuticals (United States) · USAlbany Medical Center Hospital · USColumbia University · USNew York University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe goal of this study is to use comprehensive molecular profiling to characterize clinical response to anti-TNF therapy in a real-world setting and identify reproducible markers differentiating good responders and non-responders in rheumatoid arthritis (RA).

methodsWhole-blood mRNA, plasma proteins, and glycopeptides were measured in two cohorts of biologic-naïve RA patients (n = 40 and n = 36) from the Corrona CERTAIN (Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory coNditions) registry at baseline and after 3 months of anti-TNF treatment. Response to treatment was categorized by EULAR criteria. A cell type-specific data analysis was conducted to evaluate the involvement of the most common immune cell sub-populations. Findings concordant between the two cohorts were further assessed for reproducibility using selected NCBI-GEO datasets and clinical laboratory measurements available in the CERTAIN database.

resultsA treatment-related signature suggesting a reduction in neutrophils, independent of the status of response, was indicated by a high level of correlation (ρ = 0.62; p < 0.01) between the two cohorts. A baseline, response signature of increased innate cell types in responders compared to increased adaptive cell types in non-responders was identified in both cohorts. This result was further assessed by applying the cell type-specific analysis to five other publicly available RA datasets. Evaluation of the neutrophil-to-lymphocyte ratio at baseline in the remaining patients (n = 1962) from the CERTAIN database confirmed the observation (odds ratio of good/moderate response = 1.20 [95% CI = 1.03-1.41, p = 0.02]).

conclusionDifferences in innate/adaptive immune cell type composition at baseline may be a major contributor to response to anti-TNF treatment within the first 3 months of therapy.

Indexed as

Adaptive ImmunityAdultAgedAntirheumatic AgentsArthritis, RheumatoidCohort StudiesFemaleGene Expression ProfilingHumansImmunity, InnateMaleMiddle AgedProspective StudiesTreatment OutcomeTumor Necrosis Factor-alphaAntirheumatic AgentsTumor Necrosis Factor-alphaAdaptive immune systemGene expressionInnate immune systemRheumatoid arthritisRNA-seqTNF inhibitorsTreatment responseWhole blood

Identifiers

PMID31647025
PMCPMC6813112
OpenAlexW2981986693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.